You're viewing a free preview.You're viewing a free preview — a sample of each dataset.

Research

Peer-reviewed aging research distilled into investor-relevant takeaways.

1,130 research papers tracked

Paper	Journal	Published	Relevance
Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study	The Lancet Neurology	11/01/26	Medium - Real-world plasma-protein data on how a marketed anti-amyloid drug moves blood markers, with implications for companies building Alzheimer's blood tests and treatment-monitoring panels, and for anti-amyloid developers such as Eisai and Biogen. Not yet validated for clinical use.
Do entrepreneurs live longer? A Cox survival analysis of entrepreneurship and lifespan	Journal of Business Venturing	10/22/26	Low - Observational social and occupational determinants of lifespan; of marginal relevance to longevity investing, noted for context on psychological and lifestyle drivers of healthspan.
The postpartum recovery window as a determinant of maternal aging	Trends in Endocrinology & Metabolism	10/22/26	Low-Medium - A framing paper for biological-age dynamics in women and for epigenetic clocks used in reproductive and women's-health settings; hypothesis only, no new data.
Cold activates a BH2 metabolic network promoting longevity and proteostasis	Nature	10/21/26	Medium - High-profile mechanistic work linking an environmental longevity intervention to a druggable-looking metabolic pathway (GCH1/BH4) and to protein-aggregation disease; early and in worms and cell lines, so relevance is as a target-discovery signal.
Dual Health and Economic Burden of Multimorbidity in Aging Populations	JAMA Network Open	10/21/26	Low-Medium - Quantifies the growing cost of age-related multimorbidity worldwide, which supports the market case for healthspan and prevention products; it is modeled data, not a trial or an intervention study.
Clonal Hematopoiesis and Biological Aging: An Emerging Biomarker for Longevity Medicine	Cureus	10/18/26	Low-Medium - Review (not new data) on a candidate blood-based biological-aging marker with inflammation-targeting angles; relevant to diagnostics and biomarker companies and longevity clinics, but the author states it is not yet clinically established.
Translating Geroscience Into Clinical Practice: Molecular Targets, Emerging Therapies, and Lifestyle Strategies for Healthy Longevity	Cureus	10/15/26	Low - A cautious narrative review that supports the case for evidence-based prevention over unproven geroprotectors and treats epigenetic clocks as research tools only. Useful context for assessing consumer biological-age testing and supplement claims; no new data.
Polygenic scores for longevity in relation to brain MRI measures in a cohort of 70-year-olds	npj Aging	10/15/26	Low - Basic genetic-epidemiology result linking longevity genetics to brain vascular health in men only. Background for brain-aging and genetic-risk-scoring ideas; no direct commercial implication.
Metabolomic aging and mortality clocks based on ensemble learning identify systemic aging risk across the human life span in 18,476 individuals	Science Translational Medicine	10/14/26	Medium-High - Large, prospectively followed validation of a blood-metabolite biological-age and mortality clock in a high-profile translational journal. Directly relevant to biological-age diagnostics, biomarker companies, and longevity clinics that track aging; population is Chinese, so generalizability to other groups is untested here.
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial	JAMA	10/08/26	High - A large, well-designed negative trial for the NAD+ precursor thesis in neurodegeneration. It directly undercuts disease-modifying claims for nicotinamide riboside in Parkinson disease and is a headwind for NAD+ supplement and clinic businesses that market healthspan benefits, including Niagen Bioscience (the former ChromaDex) and wellness chains selling NAD+ treatments; it does not test aging endpoints or healthy people, and one trial does not rule out other NAD+ strategies.

Showing 10 of 1,130 research papers

7-day free trial · already have an account?

Peek at other modules

News Feed

Daily longevity science headlines — aging research, deals, trials, and policy — with AI summaries.

Companies

The longevity science company universe by segment, stage, geography and capital raised.

Funding Tracker

Every disclosed longevity science round — size, stage and the investors behind it.

Clinical Trials

Longevity science and aging research trials by phase, sponsor, status and indication.

People & Movers

Who is joining, leaving and founding across longevity science and aging research.

Regulatory

FDA, EMA and policy developments that move aging research and the longevity market.